Equities Research Analysts’ updated eps estimates for Monday, October 23rd:

Aimmune Therapeutics (NASDAQ:AIMT) had its outperform rating reiterated by analysts at Credit Suisse Group. They currently have a $45.00 target price on the stock, up from their previous target price of $36.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) had its overweight rating reiterated by analysts at Piper Jaffray Companies. They currently have a $170.00 price target on the stock.

athenahealth (NASDAQ:ATHN) had its hold rating reissued by analysts at Canaccord Genuity. They currently have a $123.00 target price on the stock, down from their previous target price of $144.00.

Biogen (NASDAQ:BIIB) had its overweight rating reaffirmed by analysts at Piper Jaffray Companies. They currently have a $390.00 price target on the stock.

Bioverativ (NASDAQ:BIVV) had its overweight rating reaffirmed by analysts at Piper Jaffray Companies. The firm currently has a $71.00 price target on the stock.

Celgene Corporation (NASDAQ:CELG) had its neutral rating reiterated by analysts at Piper Jaffray Companies. The firm currently has a $133.00 price target on the stock.

CanWel Building Un (NASDAQ:CWX_UN) had its outperform rating reissued by analysts at Royal Bank Of Canada. The firm currently has a $7.50 target price on the stock.

DBV Technologies (NASDAQ:DBVT) was downgraded by analysts at Morgan Stanley to an equal weight rating.

Emerson Electric (NYSE:EMR) was upgraded by analysts at Cowen and Company to a buy rating. The firm currently has $71.00 target price on the stock. The analysts wrote, “EMR pre-announced a Q4 EPS beat with 3% organic growth and strong FCF , despite.””

Capital One Financial Corporation initiated coverage on shares of Hillenbrand (NYSE:HI). They issued an equal weight rating on the stock.

Hartford Financial Services Group, Inc. (The) (NYSE:HIG) had its hold rating reissued by analysts at Wells Fargo & Company. They currently have a $55.00 price target on the stock.

Honeywell International (NYSE:HON) had its neutral rating reaffirmed by analysts at Credit Suisse Group. The firm currently has a $150.00 price target on the stock, up from their previous price target of $141.00.

Illumina (NASDAQ:ILMN) was upgraded by analysts at Janney Montgomery Scott from a sell rating to a neutral rating.

Integer Holdings (NASDAQ:ITGR) was downgraded by analysts at Northcoast Research from a buy rating to a neutral rating.

Kansas City Southern (NYSE:KSU) had its market perform rating reaffirmed by analysts at Cowen and Company. They currently have a $113.00 target price on the stock, up from their previous target price of $111.00.

ManpowerGroup (NYSE:MAN) had its neutral rating reissued by analysts at Credit Suisse Group. Credit Suisse Group currently has a $126.00 target price on the stock, up from their previous target price of $111.00.

William Blair started coverage on shares of NuCana PLC (NASDAQ:NCNA). William Blair issued an outperform rating on the stock.

CIBC started coverage on shares of Roku (NASDAQ:ROKU). They issued a market perform rating on the stock.

William Blair started coverage on shares of Roku (NASDAQ:ROKU). William Blair issued an outperform rating on the stock.

Rio Tinto Limited (NASDAQ:RTNTF) had its sector perform rating reiterated by analysts at Royal Bank Of Canada.

Snap-On (NYSE:SNA) was upgraded by analysts at Barrington Research from a market perform rating to an outperform rating.

SunTrust Banks (NYSE:STI) was downgraded by analysts at Sandler O’Neill from a buy rating to a hold rating.

Vertical Research started coverage on shares of Tronox (NASDAQ:TROX). Vertical Research issued a buy rating on the stock.

Vertical Research started coverage on shares of Venator Materials PLC (NASDAQ:VNTR). Vertical Research issued a buy rating on the stock.

Vestas Wind Systems AS (OTCMKTS:VWDRY) had its buy rating reaffirmed by analysts at J P Morgan Chase & Co.

Wabco Holdings (NYSE:WBC) was downgraded by analysts at Vertical Research from a buy rating to a hold rating.

WSP Global (NYSE:WSP) had its outperform rating reissued by analysts at Royal Bank Of Canada. The firm currently has a $64.00 target price on the stock.

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.